A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to Clozapine

Yağcıoğlu, A. Elif Anıl; Akdede, Berna Binnur; Turgut, Tolga; Tümüklü, Murat; Yazıcı, M. Kâzım; Alptekın, Köksal; Ertuğrul, Aygün; Jayathilake, Karu; Göğüş, Ahmet; Tunca, Zeliha; Meltzer, Herbert Y.

doi:10.4088/jcp.v66n0109

Cited by 176 publications

(81 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…48,49,51 One trial reported better clinical outcomes for patients on a single antipsychotic. 47 Four of the six trials reported comparatively greater side effects for patients on multiple antipsychotics, whereas two found no differences in side effects. [47][48][49]52 One trial reported that risperidone augmentation of clozapine worsened verbal working memory, while this outcome improved in the group that remained on a single antipsychotic.…”

Section: Samples With Established Treatment Resistance To Antipsychotmentioning

confidence: 98%

“…[47][48][49][50][51][52] All studies were of patients with schizophrenia or schizoaffective disorder. Two studies found that patients on multiple antipsychotics, compared with patients on a single antipsychotic, experienced greater improvement in the primary clinical outcome (that is, symptoms or functioning).…”

Section: Samples With Established Treatment Resistance To Antipsychotmentioning

confidence: 99%

“…[47][48][49]52 One trial reported that risperidone augmentation of clozapine worsened verbal working memory, while this outcome improved in the group that remained on a single antipsychotic. 47 The RCTs had small sample sizes (16-68 patients), were relatively brief (lasting from 6 to 12 weeks), and focused on a narrow selection of antipsychotics. Five of the six trials examined antipsychotic augmentation of clozapine.…”

Section: Samples With Established Treatment Resistance To Antipsychotmentioning

confidence: 99%

“…Five of the six trials examined antipsychotic augmentation of clozapine. [47][48][49][50]52 In four trials, the augmenting agent was risperidone, [47][48][49][50] whereas in the fifth it was sulpiride 52 , an SGA not available in the United States. The sixth trial compared the combination of olanzapine and sulpiride with olanzapine monotherapy.…”

Section: Samples With Established Treatment Resistance To Antipsychotmentioning

confidence: 99%

See 3 more Smart Citations

When Is Antipsychotic Polypharmacy Supported by Research Evidence? Implications for QI

Gören

Parks

Ghinassi

et al. 2008

The Joint Commission Journal on Quality and Patient Safety

View full text Add to dashboard Cite

Section: Samples With Established Treatment Resistance To Antipsychotmentioning

confidence: 98%

Section: Samples With Established Treatment Resistance To Antipsychotmentioning

confidence: 99%

Section: Samples With Established Treatment Resistance To Antipsychotmentioning

confidence: 99%

Section: Samples With Established Treatment Resistance To Antipsychotmentioning

confidence: 99%

See 2 more Smart Citations

When Is Antipsychotic Polypharmacy Supported by Research Evidence? Implications for QI

Gören

Parks

Ghinassi

et al. 2008

The Joint Commission Journal on Quality and Patient Safety

View full text Add to dashboard Cite

“…More robust evidence is derived from four placebo controlled trials, one with sulpiride 48 and three with risperidone [49][50][51] and, due to their importance, they are summarized below. Shiloh et al showed a significant improvement on positive and negative symptoms in the group that received sulpiride added to clozapine when compared with placebo group, and it was proposed that this effect could be explained by the selective enhancement of D2 blockage by sulpiride.…”

mentioning

confidence: 99%

Esquizofrenia refratária

Elkis

Meltzer

2007

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

A b s t r a c t Objective: The aim of the present paper is to review the various aspects of refractory schizophrenia regarding issues such as definitions, clinical aspects, psychobiological correlates, pharmacological and non-pharmacological treatment options and predictors of treatment response. Method: Medline search as well as articles of the authors. Results and Conclusions: Refractory schizophrenia affects at least one third of patients with schizophrenia and the best evidence shows that is monotherapy with clozapine remains the mainstay for the treatment of such condition. Antipsychotic polipharmacy is not supported by current evidence and recent clinical trials have shown that clozapine augmentation with antipsychotics has no benefit over placebo.Descriptors: Schizophrenia/therapy; Drug utilization review; Clinical protocols; Pharmacologic actions; Treatment outcome Resumo Objetivo: O propósito deste artigo é o de revisar vários aspectos da esquizofrenia refratária levando em conta questões relacionadas a definição, aspectos clínicos, correlatos psicobiológicos, tratamentos farmacológicos e não farmacológicos, assim como preditores de resposta terapêutica. Método: Pesquisa no Medline, assim como artigos dos autores. Resultados e Conclusões: Pelo menos um terço dos pacientes com esquizofrenia são refratários a tratamento com antipsicóticos e as evidências apontam a clozapina em monoterapia como a principal opção nesses casos. A politerapia com antipsicóticos não tem apoio em evidências. Ensaios clínicos recentes mostraram que a potencialização da clozapina com outros antipsicóticos não é superior ao placebo.

show abstract